Small Cell Lung Cancer
Conditions
Brief summary
Improvements in therapy for relapsed SCLC are much needed. Paclitaxel has been previously tested and found to have significant single agent activity in relapsed SCLC, including in refractory patients. Angiogenesis plays an important role in SCLC, increased VEGF levels are associated with worse outcomes. Bevacizumab, a monoclonal antibody to VEGF, increase response rates and survival when combined with chemotherapy agents compared with the chemotherapy agent alone in NSCLC, breast cancer, and colorectal cancer. Paclitaxel plus bevacizumab, in the dose and schedule proposed in this study, improves response rates and progression free survival compared with paclitaxel alone in women with metastatic breast cancer. Therefore, we will be testing the safety, feasibility, and efficacy of this regimen in patients with chemosensitive relapsed SCLC.
Detailed description
OUTLINE: This is a multi-center study. Paclitaxel 90 mg/m2 IV infusion over 1 hour days 1, 8 and 15 of 28 day cycle Plus Bevacizumab 10 mg/kg on days 1 and 15 of 28 day cycle. * 1 cycle = 28 days (4 weeks) * Disease assessments will be performed per RECIST every other cycle * After a minimum of 4 cycles or a maximum of 6 cycles of combination chemotherapy, bevacizumab monotherapy may continue until disease progression or intolerable side effects ECOG Performance Status 0 or 1 Hematopoietic: * White blood cell count \> 3,000 mm3 * Absolute neutrophil count (ANC) \> 1,500 mm3 * Platelet count \> 100,000 mm3 * International normalized ration (INR) of prothrombin time ≤ 1.2 * PTT no more than 5 seconds longer than the ULN Hepatic: * Bilirubin \< 1.5 x ULN * Aspartate aminotransferase (AST, SGOT) \< 2.5 x ULN Renal: * Urine protein:creatinine ratio \<1.0 Cardiovascular: * No history of myocardial infarction or angina pectoris/anginal equivalent in the last 6 months. Note: The patient may be on anti-anginal medications if the symptoms have been entirely controlled for greater than 6 months. * No history of uncontrolled congestive heart failure or uncontrolled hypertension
Interventions
DRUGPaclitaxel
Paclitaxel 90 mg/m2 IV infusion over 1 hour, days 1, 8 and 15 of 28 day cycle.
DRUGBevacizumab
Bevacizumab 10 mg/kg, days 1 and 15 of 28 day cycle
Sponsors
Genentech, Inc.
Walther Cancer Institute
Hoosier Cancer Research Network
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologic or cytologic proof of small cell lung cancer * Chemo-sensitive disease defined as relapsed after 60 days from completion of first line chemotherapy. * Measurable disease according to RECIST and obtained by imaging within 28 days prior to being registered for protocol therapy. * Must have received treatment with at least 1 but not more than 2 prior chemotherapy regimens. (At least one regimen must contain a platinum agent. Previous treatment with irinotecan is allowed.) * Prior radiation therapy must be completed at least 21 days prior to being registered for protocol therapy, and toxicities due to radiation must have recovered to ≤ grade 1 or baseline prior to registration. * Prior cancer treatment must be completed at least 21 days prior to being registered for protocol therapy and the subject must have recovered from the acute toxicity effects of the regimen prior to registration.
Exclusion criteria
* No treatment with any investigational agent within 30 days prior to being registered for protocol therapy. * No history or radiographic evidence of CNS involvement by head CT or MRI within 42 days prior to registration. * No history of seizures, transient ischemic attack or stroke. * No clinically significant infections as judged by the treating investigator. * No other active cancer except SCLC. * No prior treatment with topoisomerase I inhibitor. * No contraindications to the use of paclitaxel or bevacizumab as per the investigator's clinical judgment. * Must not have grade 3 or greater peripheral neuropathy. * Must not have had major surgical procedure, open biopsy, or significant traumatic injury within 28 days of being registered for protocol therapy. * No anticipation of need for major surgical procedure during the course of the study. * Patients may not have had a minor surgical procedure, placement of an access device or fine needle aspiration within 7 days prior to being registered for protocol therapy. * No evidence of bleeding diathesis or coagulopathy. * No history of deep vein thrombosis or pulmonary embolism. * No full dose/therapeutic anticoagulation with either low molecular weight heparin or unfractionated heparin or coumadin within 10 days prior to registration. * Patients must not have been using aspirin (\>325 mg/day) or another nonsteroidal anti-inflammatory medications known to inhibit platelet function on a daily basis within 10 days prior to registration on study. * Patients must not be using any of the following drugs known to inhibit platelet function within 10 days prior to registration: dipyridamole (Persantine), ticlopidine (Ticlid), clopidogrel (Plavix) and cilostazol (Pletal). * Patients must not have a current non-healing wound or fracture. * Patients must not have a history of or current hemoptysis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine progression free survival(PFS) of this regimen in patients with chemosensitive relapsed small cell lung cancer (SCLC). | 18 months |
Secondary
| Measure | Time frame |
|---|---|
| To assess VEGF polymorphisms in the study population. | 18 months |
| To determine the response rate of the combination of paclitaxel and bevacizumab with chemosensitive SCLC. | 18 months |
| To determine the toxicity of the combination of paclitaxel and bevacizumab in patients with SCLC. | 18 months |
| To determine overall survival. | 18 months |
Countries
United States
Outcome results
None listed